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Translational relevance  
 
TCR-engineered adoptive T cell transfer has shown a high frequency of transient antitumor 
responses in several clinical trials but has been followed by a high relapse rate. Persistence and 
continuous functionality of the engineered T cells are thought to be an important component to 
achieve long-term responses. We propose a clinical trial to co-administer genetically modified T 
cells and hematopoietic stem cells (HSCs) expressing an NY-ESO-1 TCR to generate a source 
for constant renewal of TCR-engineered T cells. The clinical trial proposed here will serve as a 
proof-of-concept to demonstrate the feasibility and efficacy of gene-modified stem cell therapy 
to genetically redirect the immune response to cancer.   
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Abstract 
Purpose: To improve persistence of adoptively transferred T cell receptor (TCR)-engineered T 
cells and durable clinical responses, we designed a clinical trial to transplant genetically-
modified hematopoietic stem cells (HSCs) together with adoptive cell transfer (ACT) of T cells 
both engineered to express an NY-ESO-1 TCR. Here, we report the preclinical studies 
performed to enable an investigational new drug (IND) application. 
 
Experimental design: HSCs transduced with a lentiviral vector expressing NY-ESO-1 TCR and 
the PET reporter/suicide gene HSV1-sr39TK and T cells transduced with a retroviral vector 
expressing NY-ESO-1 TCR were co-administered to myelodepleted HLA-A2/Kb mice within a 
formal GLP-compliant study to demonstrate safety, persistence and HSC differentiation into all 
blood lineages. Non-GLP experiments included assessment of transgene immunogenicity and 
in vitro viral insertion safety studies. Furthermore, GMP-compliant cell production qualification 
runs were performed to establish the manufacturing protocols for clinical use. 
 
Results:  TCR genetically-modified and ex vivo cultured HSCs differentiated into all blood 
subsets in vivo after HSC transplantation, and co-administration of TCR-transduced T cells did 
not result in increased toxicity. The expression of NY-ESO-1 TCR and sr39TK transgenes did 
not have a detrimental effect on gene-modified HSCs differentiation to all blood cell lineages. 
There was no evidence of genotoxicity induced by the lentiviral vector. GMP batches of clinical-
grade transgenic cells produced during qualification runs had adequate stability and 
functionality. 
 
Conclusion: Co-administration of HSCs and T cells expressing an NY-ESO-1 TCR is safe in 
preclinical models. The results presented in this manuscript led to the U.S. FDA approval of IND 
17471.   
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Introduction 
 
Adoptive transfer of T cells genetically modified to express tumor-specific T cell receptors (TCR) 
has shown remarkable antitumor efficacy in several clinical trials (1–7). However, durable long- 
term clinical responses have been more challenging to maintain (4,6), while engraftment and 
persistence of the modified T cells have been associated with better antitumor responses 
(4,5,8).  
 
To improve the persistence of the TCR-expressing T cells, we propose to use genetically 
modified hematopoietic stem cells (HSCs) as a source for constant endogenous renewal of 
TCR-engineered T cells. The use of genetically modified HSCs was first shown to be efficacious 
in primary immunodeficiencies, where the transplantation of genetically modified HSCs 
demonstrated long-term correction of the disease (9–11). Regarding its use in cancer 
immunotherapy, it has been previously shown in murine and humanized murine models that 
transplantation of HSCs engineered to express a tumor-specific TCR results in the output of 
functional T cells with the defined specificity after proper thymic selection. The newly generated 
T cells showed antitumor activity, and were able to differentiate into memory T cells after 
antigen stimulation (12–18). The endogenously produced TCR-engineered T cells demonstrated 
allelic exclusion, a process in which the TCR transgenic chains inhibit the expression of the 
endogenous TCR chains, thereby avoiding TCR mispairing and consequently reducing the 
potential toxicity of the therapy (19). 
 
To test the approach of TCR genetic engineering of HSCs in the clinic, we designed a clinical 
trial of double cell therapy co-administering HSCs and T cells both genetically modified to 
express an NY-ESO-1 TCR. We propose to use two TCR-engineered cell therapies because we 
anticipate that the TCR-engineered HSCs will endogenously differentiate into fully active mature 
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T cells with a long delay in their appearance in the periphery, as new T cells reaching peripheral 
circulation must undergo a thymic selection process which takes one to three months (20,21). In 
this clinical trial, TCR-engineered mature lymphocytes and TCR-engineered HSCs will be co-
administered to patients with NY-ESO-1-positive advanced cancers after a myelo- and 
lymphodepleting conditioning regimen. We hypothesize that the TCR-engineered mature 
lymphocytes will expand in vivo and provide the first wave of transient antitumor activity. This 
will serve as a bridge until the second wave of TCR-transgenic cells arising from the bone 
marrow-engrafted gene-modified HSCs has gone through the T lymphocyte maturation process 
and partially repopulated peripheral tissues (Supplemental Figure 1). 
 
We propose to use the NY-ESO-1 TCR for this clinical trial since the toxicities observed in 
adoptive T cell therapy clinical trials using this TCR were not dose-limiting and unrelated to the 
TCR recognizing its cognate antigen, which in adult life is presented by the cancer cells and 
absent in most normal somatic cells (3,5,6). NY-ESO-1 is a cancer-testis antigen expressed at 
high homogeneous levels in synovial sarcoma, with lower frequency of expression in melanoma 
and multiple myeloma, and at even lower levels in other cancers (22–24). The NY-ESO-1 TCR 
used in this work recognizes the SLLMWITQC NY-ESO-1 epitope in the context of HLA-A*0201 
and contains a two amino acid substitution in the third complementary determining region that 
increases its affinity for peptide-MHC complexes (25).   
 
Herein we report on preclinical studies performed to demonstrate the safety and feasibility of the 
approach. These studies led to the investigational new drug (IND) application approval for a 
new clinical trial that is being conducted at UCLA (NCT03240861). Based on the previous 
experience with adoptive T cell transfer using the NY-ESO-1 TCR, the major safety concerns 
were focused on the transplantation with lentivirally modified HSCs and the untested effects of 
the co-administration of the HSCs and T cells both expressing the same NY-ESO-1 TCR. The 
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preclinical studies performed to justify the safety of our approach adressed: i) the ability of the 
genetically modified and ex vivo cultured Lin- cells to differentiate into all blood lineages; ii) the 
effect of the co-administration of genetically modified Lin- cells and T cells on the engraftment 
and proliferation of the T cells and the engraftment and differentiation of the HSCs; iii) the 
immunogenicity of the NY-ESO-1 TCR and the sr39TK transgenes caused by their expression 
in the various hematopoietic cells; iv) the potential genotoxicity induced by the lentiviral vector 
integration in the Lin- cells; and v) the ability of the sr39TK suicide gene to ablate transduced 
stem cell progeny in case of a serious adverse event. To test the feasibility of the clinical trial, 
we validated the HSC cell product manufacturing process and demonstrated the stability and 
functionality of the final product. The data presented on the manuscript is focused on the 
approach-specific studies. Detailed information on the viral vector manufacturing, lot release 
criteria and optimization of the gene modified cell manufacturing can be found in the 
Supplemental Data Section.    
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Materials and Methods 
 
Bone marrow transplantation (BMT) experiments: All animal experiments were performed 
under the UCLA Animal Research Committee protocol #2013-095 that was previously approved 
by the IACUC. Lin- cells were isolated from the bone marrow of HLA-A2/Kb transgenic mice 
(26), pre-stimulated with cytokines, transduced with previously validated lentiviral vectors LV-
NY-ESO-1 TCR/sr39TK, LV-NY-ESO-1 TCR, or LV-empty and cultured in vitro. For the co-
administration experiments, T cells were isolated from spleens from HLA-A2/Kb transgenic mice, 
activated with CD3/28 and IL-2 stimulation, transduced with the RV-NY-ESO-1 TCR and 
expanded in vitro. The methods and reagents to manufacture and validate both cell products 
are described in the supplemental materials. Transduced Lin- cells alone or together with 
transduced T cells were administered systemically to 8- to 12-week-old HLA-A2/Kb mice that 
had received total body irradiation with 900cGy the day prior to cell administration. A detailed 
description of the cell testing performed prior to administration and the cell doses can be found 
in the supplemental material and methods. Five days or three months after the BMT, mice were 
euthanized and hematology, serum chemistry, complete histopathology survey, lentivirus and 
retrovirus vector copy number (VCN) in the blood, spleen and bone marrow and TCR 
expression and phenotype analysis in the bone marrow and spleen were performed. A detailed 
explanation of these procedures can be found in the supplemental material and methods.    
 
In vitro immortalization assays: Lin- cells from C57BL/6J (Jackson Laboratories, Bar Harbor, 
ME) mice were transduced with the LV-NY-ESO-1 TCR/sr39TK vector or the retrovirus SF91-
eGFP-WPRE, expanded and seeded at limiting dilution. The growth of transformed clones was 
measured. This procedure is detailed in the supplemental material and methods. 
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LV-NYESO TCR/sr39TK Peripheral Blood Stem Cells (PBSC) manufacturing and stability 
evaluation: The CD34+ cell population was enriched using the CliniMACS®CD34 reagent 
system, pre-stimulated overnight and transduced with LV-NYESO TCR/sr39TK vector 
supernatant at a final multiplicity of infection (MOI) of 50 (two transduction cycles of 25 MOI 
each). After 18±6 hours from the first transduction, cells were harvested, formulated in 
cryopreservation solution and cryopreserved using a controlled-rate freezer. The cell product 
was tested for sterility, endotoxin levels, mycoplasma contamination, clonogenic potential and 
transduction efficiency. Long-term stability of the cryopreserved cell product was evaluated 
30±7, 90±7 and 180±10 days post-cryopreservation. The post-thaw stability of the cell product 
was tested over a 48-hour period.  See supplemental material for further details. 
 
Statistical analysis: Described in the supplemental materials. 
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Results 
 
Generation of clinical-grade lentiviral and retroviral vectors expressing NY-ESO-1 TCR 
The lentiviral vector used in this clinical trial, LV-NY-ESO-1 TCR/sr39TK (RRL-MSCV-
optNYESO-optsr39TK-WPRE, Figure 1A), expresses the alpha and beta chains of the NY-ESO-
1 TCR and the sr39TK suicide/PET reporter gene linked by a 2A self-cleavage peptide, and has 
been previously described in preclinical studies (17). The expression of the transgenes is driven 
by the murine stem cell virus (MSCV) promoter derived from the MSCV retrovirus long terminal 
repeat (LTR). Both genes had been codon-optimized to improve expression in mammalian cells. 
This vector was produced at Good Manufacturing Practice (GMP) grade at the Indiana 
University Vector Production Facility (IU VPF). To have enough vector for all of the IND-
enabling studies and product manufacture optimization, a first manufacture of a 20-liter 
preparation without full lot release testing was labeled as GMP-comparable lot and was used for 
the majority of the preclinical studies. A second GMP production of 60 liters that was tested and 
met all of the lot release criteria (Supplemental Tables 1 and 2) was used for preclinical studies 
of cell product manufacturing and functionality, and will be used for clinical product 
manufacturing. To characterize the functionality of the lentiviral vector, we measured: i) the 
expression of the NY-ESO-1 TCR on the cell surface by dextramer staining in transduced 
human PBMCs (Figure 1B); and ii) the sr39TK suicide gene function in transduced human 
CD34+ peripheral blood stem cells (PBSC). Following treatment of human CD34+ PBSC with 
increasing doses of ganciclovir in vitro, the number of NY-ESO-1 TCR-positive cells (Vβ13+ 
cells) decreased while the number of TCR-negative cells remained constant (Figure 1C).  
 
To genetically engineer the peripheral T cells for short-term anti-tumor activity while awaiting the 
emergence of TCR transgenic T cells from the transplanted HSCs, a preparation of 18 liters of 
GMP-grade retroviral vector expressing the NY-ESO-1 TCR chains, RV-NY-ESO-1 TCR 
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(MSGV1-A2ab-1G4A-Ly3H10), was made at the IU VPF. The vector met all of the release 
criteria (Supplemental Table 3). This retroviral vector is a splicing-optimized MSCV-derived 
vector expressing the alpha and the beta chains of the NY-ESO-1 TCR linked by a P2A self-
cleavage peptide (a kind gift from Dr. Steven A. Rosenberg and Dr. Paul Robbins, Figure 1D). 
For the studies in mice presented in this manuscript, we pseudotyped the clinical vector with an 
ecotropic envelope, and a 3-liter GMP-comparable batch was produced at the IU VPF. For the 
GMP-comparable vector, only partial lot release testing was performed (Supplemental Table 4). 
To demonstrate the functionality of the ecotropic RV-NY-ESO-1 TCR retroviral vector, we 
transduced murine T cells from HLA-A2/Kb mice and measured the expression of extracellular 
and surface NY-ESO-1 TCR staining for the beta chain of the TCR (Vβ13 staining, Figure 1E). 
 
Preparation for a Good Laboratory Practice (GLP) study in an academic setting 
To formally test if the co-administration of both cell products is safe, it was necessary to set up 
all of the conditions required to conduct a complete toxicology study under GLP conditions in 
compliance with 21 CFR Part 58. As GLP studies require exclusively dedicated facilities, a new 
laboratory space was set up with certified and calibrated equipment, with continuous automated 
monitoring of all the equipment and a tracking system in place to assure that the raw materials, 
test articles and specimens were adequately preserved. One-hundred-twelve standard 
operating procedures (SOPs) were generated that captured all of the intended procedures for 
the study, including the specifics of the scientific protocols, facility and equipment management, 
personnel training and GLP procedures. All of the personnel involved in the study were qualified 
to perform their assignments, and curricula vitae, job descriptions and training records were 
maintained to document their proficiency. The study required 32 personnel with job descriptions 
previously defined and recorded (see organizational chart in Supplemental Figure 2). All 
personnel were required to undergo documented training to conduct GLP studies and to 
perform the procedures for which they were responsible. In addition, all personnel were required 
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to demonstrate proficiency using the pertinent SOPs according to their job descriptions. Prior to 
study initiation, the identity, purity and potency of the test articles were verified, acceptance 
criteria for the manufactured cells were established, and the study protocol was approved by the 
study director, the test facility management and the sponsor. This documentation was included 
in the IND later submitted to the FDA. Before the beginning of the study, a master schedule was 
generated and distributed to all personnel involved in the study. Sterility testing, blood and 
serum analysis and histopathology analysis were outsourced to GLP-compliant contract 
research organizations. The study included a full histopathological analysis performed by an 
ACVP board-certified veterinary pathologist.  All raw data were signed by the study personnel 
performing the activity, reviewed by the study director or designee and archived. Any deviation 
from the SOPs, study protocol or GLP regulations was summarized in a deviation report, and its 
impact on the study data addressed by the study director and archived with the study 
documentation. All of the data generated in the study were included in a final study report that 
was submitted to the FDA in support of the IND application. All of the study raw data, specimens 
and test articles will be archived for 5 years after submission of the IND to the FDA. Finally, an 
independent Quality Assurance Unit audited all of the experimental portions of the study, the 
facilities, the SOPs, the study records and the GLP report and generated a Quality Assurance 
statement that was included in the final study report.  
 
Establishment of a suitable syngeneic mouse model for the GLP testing of dual TCR-
engineered cell therapy 
Fully immunocompetent HLA-A2/Kb transgenic mice express a chimeric MHC class I complex 
that includes the human HLA-A2.1 α1 and α2 domains, allowing their cells to present the same 
epitopes as HLA-A2.1 subjects, and maintain the murine α3 domain, permitting murine CD8 co-
receptor engagement (26). To manufacture the T cell products, T cells from HLA-A2/Kb mice 
were activated, transduced with the RV-NY-ESO-1 TCR vector and expanded ex vivo. For the 
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HSC product, lineage-negative (Lin-) progenitor stem cells were purified from the bone marrow 
of HLA-A2/Kb mice, pre-stimulated with cytokines and transduced with the LV-NY-ESO-1 
TCR/sr39TK vector. Both cell types were co-administered by tail vein injection to myelodepleted 
HLA-A2/Kb mice that had previously received a lethal dose of total body irradiation (TBI, 900 
cGy). We performed twelve pilot studies to establish the best conditions for bone marrow 
transplantation (BMT) in this model. The main conclusions from these pilot studies were: i) TBI 
at 900cGy is myelodepleting and lethal without BMT (Supplemental Figure 3A); ii) specific 
animal care procedures had an important role, in particular having long acclimatization periods 
in the animal facility before treatment, preventive antibiotic treatment, and supplementary 
hydration and nutritional gel diet during the post-irradiation recovery; iii) culture of Lin- cells for a 
short time, 48 hours, was important for HSCs engraftment, progeny persistence and survival 
(Supplemental Figure 3B); iv) doses from 0.5-2 x 106 short culture (48 hours) Lin- cells showed 
no differences in engraftment and survival (Supplemental Figure 3C); and v) increasing the 
retrovirus vector copy number (VCN) in T cells was not toxic (Supplemental Figure 3D).  
 
GLP toxicity study demonstrating that co-administration of TCR-engineered Lin- cells 
and T cells is safe and does not affect the engraftment and differentiation of progeny 
cells 
The formal GLP-compliant toxicity study design is described in detail in the study protocol 
(Supplemental Materials section 4). This study included a total of 110 mice divided into five 
groups (Supplemental Table 5). The number of mice had been prospectively defined by power 
calculation based on the assumptions made after interpreting the pilot studies (see study 
protocol in the Supplemental Materials section 4). TCR-transduced Lin- cells and TCR-
transduced T cells (cohort E) were co-administered to myelodepleted HLA-A2/Kb mice and 
compared with control groups of mice receiving mock-transduced Lin- cells and mock-
transduced T cells (cohort B), transduced Lin- cells and mock-transduced T cells (cohort C), 
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mock-transduced Lin- cells and transduced T cells (cohort D), or untreated control mice (cohort 
A). Different cohorts of mice were euthanized at five days or three months after BMT to allow 
analyses of toxicity without interfering with the overall survival endpoint (Supplemental Table 5). 
Prior to the study start, we established acceptance criteria for the cell manufacture, and planned 
to not proceed with any batches of cells that did not meet the criteria. The criteria included cell 
purity, viability, VCN, mycoplasma, sterility, endotoxin, cell mix homogeneity and stability during 
administration (Supplemental Table 6).  
 
After BMT and T cell administration, mice were followed for three months. No differences in 
overall survival were observed among cohorts (log-rank test p-value 0.48, Figure 2A). A 
statistically significant decrease in total body weight was observed in all cohorts receiving TBI 
and BMT compared to the untreated mice, but it was independent of the expression of the NY-
ESO-1 TCR and sr39TK transgenes (Figure 2B, Supplemental Figure 4).  
 
Overall, the clinical observations, gross pathology and histopathology from the 10 animals that 
died or were euthanized before the end of the study did not identify toxicities that could be 
attributed to a specific treatment leading to increased mortality of a specific cohort. Lack of 
engraftment together with intestine necrosis was observed in the three mice that died within the 
first two weeks after BMT: one in cohort C (transduced Lin- cells and mock T cells), one in 
cohort D (mock Lin- cells and transduced T cells) and one in cohort E (transduced Lin- cells and 
transduced T cells). Necrotic intestines and cecal torsions associated with irradiation sickness 
were also observed in two additional mice from cohort C (transduced Lin- cells and mock T 
cells) that died at day 64 and 69 after BMT. Urethral obstruction and urinary bladder distension 
were observed in one mouse from cohort C that died at day 52 after BMT (transduced Lin- cells 
and mock T cells) and one from cohort D that died at day 21 after BMT (mock Lin- cells and 
transduced T cells). Additionally, one mouse from cohort A (untreated) died at day 71 
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presenting an atypical enlargement of the heart. No significant findings were identified in one 
mouse from cohort B (mock Lin- cells and mock T cells) that died at day 35 and one from cohort 
E (transduced Lin- cells and transduced T cells) that died at day 85.  We performed a full 
necropsy for all of the mice euthanized at the study end, three months after treatment. The 
necropsy included organ weights (Figure 2C) and histopathology of all protocol-specified 
collected tissues (Supplemental Table 7). A marked reduction in testes weight was observed in 
all cohorts receiving TBI, consistent with germ cell ablation identified by histopathology analysis. 
No other consistent microscopic findings associated with a treatment or with irradiation were 
identified.  
 
Complete blood cell counts (CBC) at day 5 after BMT showed that mice receiving TBI were 
lymphodepeleted and presented with statistically significant decreases in red blood cell and 
platelet counts (Figure 2D and E, Supplemental Figure 4C). TBI caused a sharp reduction in 
splenocyte and bone marrow cell counts, with a decrease in spleen weight that was recovered 
three months after BMT (Supplemental Figure 5). At three months after BMT, mice from all 
cohorts had reconstituted all blood cell compartments. All white blood cell lineages had 
recovered completely (Figure 2D and E), and red blood cell parameters (RBC, hemoglobin and 
hematocrit) were slightly increased in irradiated mice while platelets were not completely 
recovered relative to untreated mice (Figure 2D and Supplemental Figure 4). Serum chemistry 
analysis at three months after BMT showed a slight decrease in albumin levels in the co-
administration group (cohort E). Liver function tests and creatinine kinase activities were highly 
variable and in general increased in all cohorts receiving BMT (Figure 2 F and Supplemental 
Figure 6). However, there was no evidence of hepatocyte or muscle damage in tissue sections 
or the clinical observations. Altogether, these data demonstrate that the co-administration of Lin- 
cells and T cells expressing an NY-ESO-1 TCR is safe and does not increase toxicity beyond 
those related to the BMT procedure. 
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To assess the engraftment and persistence of the T cells and Lin- cells expressing the NY-ESO-
1 TCR, we quantified the VCN using droplet digital PCR (ddPCR) with primers specific for the 
inserted retroviral and lentiviral vectors. We demonstrated the presence of transduced T cells at 
five days and three months after treatment in blood, spleen and bone marrow cells with no 
statistical difference between the groups receiving mock transduced Lin- cells or NY-ESO-
1/sr39TK-transduced Lin- cells together with the transduced T cells (Figure 3A and B). Similarly, 
we quantified the engraftment of the transduced Lin- cells and the persistence of their progeny 
five days and three months after treatment in blood, spleen and bone marrow. No statistically 
significant differences were identified among the cohorts receiving transduced Lin- cells 
together with mock-transduced T cells or with NY-ESO-1 TCR-transduced T cells (Figure 3C 
and D).  
 
Finally, to study the differentiation of the Lin- cells, we performed an extensive phenotype 
characterization of the bone marrow cells and splenocytes three months after BMT. In the bone 
marrow, there were no differences in the frequencies of HSCs and precursor populations, Lin-, 
LSK (Lin-, ScaI+, cKit+) and HSCs (LSK, CD150+ CD48-), among the cohorts receiving BMT, 
although the frequency of Lin- and HSCs populations was decreased compared to untreated 
mice (Figure 4A and Supplemental Figure 7). Intracellular expression of the NY-ESO-1 TCR by 
clonotypic Vβ13 staining was observed in mice receiving BMT with TCR-transduced Lin- cells 
independently of the T cells received (Figure 4B and Supplemental Figure 7). Interestingly, 
there were no differences in the frequencies of the Lin-, LSK and HSCs cells between the total 
bone marrow and the Vβ13+ population (Figure 4C and Supplemental Figure 7). Similarly, 
phenotypic characterization in the spleen showed no differences in NKT cells, CD4+ T cells, 
CD8+ T cells, B cells, granulocytes, neutrophils and monocytes/macrophages among all cohorts 
receiving BMT, although there was a decrease in the NKT cell population and an increase in the 
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CD4+ T cell population when compared to the untreated mice (Figure 4D and Supplemental 
Figure 7). Intracellular NY-ESO-1 TCR was expressed in the cohorts receiving transduced Lin- 
cells independent of the T cells received (Figure 4E and Supplemental Figure 7). The NY-ESO-
1 TCR-positive cells displayed an increase in CD8+ T cells, NKT and macrophages and a 
decrease in CD4+ T cells compared to the total splenocyte population (Figure 4F and 
Supplemental Figure 7).  
 
Lack of immunogenicity due to the expression of NY-ESO-1 TCR and sr39TK by Lin- cells 
progeny after BMT in myelodepleted mice  
To test if the expression of the NY-ESO-1 TCR and the sr39TK in the hematopoietic cell 
progeny after BMT in myelodepleted hosts is immunogenic, we performed BMT experiments 
with Lin- cells transduced with the lentiviral vectors expressing the NY-ESO-1 TCR and the 
sr39TK, the NY-ESO-1 TCR alone, or an empty vector using the same animal model described 
above. We demonstrated that after the BMT, engraftment was observed in mice from all cohorts 
with no difference in survival (Supplemental Figure 8A). The peripheral blood cell populations 
were reconstituted three months after BMT, and no significant differences were observed 
among cohorts in the white cell and red blood cell populations (Figure 5A and Supplemental 
Figure 8B). As seen in the co-administration experiment, at three months the platelets had not 
completely recovered to the level of untreated control mice (Figure 5A). To test the potential 
immunogenicity of the transgenes, we assessed the engraftment and persistence of modified 
Lin- cells progeny by VCN quantification using primers designed within the lentivirus packaging 
signal to be able to detect the three lentiviruses. If the transgenes were immunogenic, then we 
would anticipate that cells expressing NY-ESO-1 TCR and sr39TK would not persist long term. 
As the engraftment and persistence of the transduced stem cell progeny in the bone marrow, 
spleen and blood were not affected by the expression of the transgenes (Figure 5B), we 
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concluded that expression of the NY-ESO-1 TCR and sr39TK was not immunogenic three 
months after autologous BMT in this immunocompetent mouse model.      
 
Lack of genotoxicity of the LV-NY-ESO-1 TCR/sr39TK vector in murine Lin- cells  
To assess the potential genotoxicity of the lentiviral vector in Lin- cells, we performed an in vitro 
immortalization (IVIM) experiment (27). Briefly, Lin- stem cells from C57BL/6J mice were 
purified and either mock-transduced, transduced with the retroviral vector SF91-eGFP-WPRE 
(28), or transduced with the LV-NY-ESO-1 TCR/sr39TK lentiviral vector. The retrovirus SF91-
eGFP-WPRE is known to be oncogenic and to integrate preferentially close to cancer-related 
genes (27,29,30), thereby serving as a positive control for the IVIM experiment. The Lin- cells 
were cultured in bulk for two weeks and then seeded in limiting dilution and cultured for an 
additional two weeks. At the end of the expansion, the replating frequency/VCN ratio was 
measured. Transformation occurred in eight out of the 20 independent assays performed with 
the cells transduced with the positive control vector, SF91-eGFP-WPRE. In contrast, no growth 
was observed in the mock-transduced Lin- cells (n=3) or the Lin- cells transduced with LV-NY-
ESO-1 TCR/sr39TK (n=17) (Figure 5C). These data demonstrated lack of genotoxicity of the 
vector proposed for use in our clinical trial by the IVIM assay. 
 
Human PBSC product manufacturing validation, functionality and stability of the final 
product 
For the chemistry, manufacturing and controls (CMC) section of the IND, we performed five 
manufacturing validation runs together with their lot release testing. Three of the validation runs 
were performed using the GMP-compliant clinical-grade vectors. We purchased granulocyte-
colony stimulating factor (G-CSF)-mobilized peripheral blood leukapheresis products obtained 
from healthy human donors and enriched them for CD34+ PBSC using a clinical grade 
magnetic sorting system. Analysis of five enrichment procedures demonstrated mean CD34+ 
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fraction purity of 96% and viability of 92%. Following enrichment, the cells were stimulated for 
approximately 18 hours in X-Vivo 15 media supplemented with rhSCF, rhTPO, rhFLT3L and 
rhIL-3 and transduced with the lentiviral vector encoding NY-ESO-1 TCR and sr39TK for an 
additional 18 hours. Following the transduction, the PBSC were harvested and cryopreserved; 
average cell viability was 95%. An aliquot evaluated for bacterial, fungal, and mycoplasmal 
contamination using both organism-specific cultures and multiple histological stains 
demonstrated no infections. Endotoxin levels were ≤ 5 EU/Kg of body weight. We assessed the 
transduction efficiency of PBSC with the LV-NY-ESO-1 TCR/sr39TK vector by VCN with an 
average of 0.3. The percentage of cells expressing NY-ESO-1 TCR (by Vβ13 staining) was 
24%, and the percentage of colony-forming units (CFU) positive for Psi (Ψ) sequence was 33%. 
These results show the feasibility of the manufacturing procedure and were used to establish 
the lot release acceptance criteria for the clinical trial batches (See Supplemental Table 8 
summarizing the cell product specifications for all of the qualification runs and Supplemental 
Material Section 5 containing the CMC section of the approved IND).  
 
To study the effect of gene-modification on PBSC functionality, we compared the clonogenic 
potential of PBSC product to that of freshly isolated peripheral blood CD34+ cells and 
untransduced CD34+ cells cultured under the same conditions. The clonogenic potential of 
peripheral blood CD34+ cells was similar between the groups as established by percentage of 
CFU per total cells plated. The average percentage of CFUs was 39±11%, 48±6% and 51±11% 
(n=5, p=0.1), respectively, in the unstimulated, untransduced and transduced PBSC final 
product. Finally, we showed that the transduced and in vitro-cultured stem cells were able to 
differentiate in vitro in artificial thymic organoids into functional T cells expressing the NY-ESO 
TCR (Supplemental Figure 9), as previously described by Seet and co-workers (31). 
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To measure the stability of the TCR-transduced HSCs product, we confirmed that the total cell 
viability, CD34 recovery and clonogenic potential as well as the CFU subtype distribution were 
not affected after 1, 3 and 6 months post-cryopreservation (Figures 6A and B). See 
Supplemental Table 9 and supplemental material section 6 for the detailed description of the 
stability evaluation for the LV-NYESO TCR/sr39TK PBSC product. In addition, we evaluated the 
post-thaw stability of the PBSC product after 3, 6, 24 and 48 hours. The cells were split and 
stored at either ambient room temperature (RT) or 4-8°C. Based on the results of CD34+ cell 
viability and clonogenic potential, we concluded that the PBSC product should be stable for up 
to 6 hours post-thawing. Although no significant changes in total cell viability were observed 
(Figure 6C) the number of viable CD34+ cells in the cell product was significantly decreased in 
both storage conditions after 24h (Figure 6D). The percent CFU per total cells plated 
significantly decreased after 24 hours in both storage conditions, from 46% to 13% (RT) and 
29% (4-8°C) (Figure 6E). The average recovery of CD34+ cells after 24h in storage at RT 
decreased to 81%, whereas no significant change in recovered CD34+ cells was observed 
while stored at 4-8°C (Figure 6F).   
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Discussion 
 
The IND-enabling studies presented herein were performed based on the written requirements 
from FDA reviewers discussed at a pre-IND meeting. The safety concerns regarding the 
proposed clinical trial were mainly focused on the effect of ex vivo modification of HSCs with 
lentiviral vectors on genotoxicity and stem cell differentiation and the effect of the co-
administration with TCR-transduced T cells. Our studies demonstrate that neither of these 
concerns were evident in preclinical models. Accordingly, the proposed clinical trial has 
subsequently been approved by the FDA to proceed to patient accrual. 
 
We have previously shown that human CD34+ cells transduced with the same lentiviral vector 
and ex vivo-cultured were able to engraft in myelodepleted neonatal NSG HLA-A2.1 mice and 
differentiate into B cells and functional T cells (17). In these experiments, we have also 
demonstrated that the modified HSCs and their progeny could be tracked using PET/CT scan 
and could be completely ablated following ganciclovir treatment (17). We also have 
demonstrated that human CD34+ cells transduced with the LV-NY-ESO-1 TCR vector were 
able to differentiate in vitro in artificial thymic organoids to functional T cells with tumor antigen-
specific cytotoxicity and near-complete lack of endogenous TCR Vβ expression due to allelic 
exclusion (31). In the current studies using immunocompentent mouse models, we have 
established that co-administration of genetically modified Lin- cells and T cells does not affect 
the engraftment and persistence of T cells and the engraftment, differentiation and progeny 
persistence of the Lin- cells. Based on these new results, we conclude that the expression of 
NY-ESO-1 TCR and sr39TK do not alter the differentiation of the Lin- cells or the persistence of 
their progeny, supporting the lack of immunogenicity of these transgenes after BMT in 
myelodepleted mice. Overall, these data indicate that co-administration of TCR-engineered T 
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cells and TCR-engineered HSCs represents a viable means of obtaining cells capable of 
mounting both an immediate and a prolonged tumor-targeted immune response.   
 
A concern regarding the HSCT with lentivirally transduced HSCs is the potential genotoxicity of 
the vector caused by its integration close to cancer-related genes leading to clonal expansion, a 
process termed insertional mutagenesis. This concern arises from previous clinical trials using 
gamma-retroviral vectors that preferentially integrate near oncogenes (LMO2, MDS1-EVI1, 
PRDM16, SETBP1, CCND2 among others) and deregulate their expression due to the strong 
viral promoters located in their LTRs; this phenomenon led to the development of leukemia and 
myelodysplasia in the first gene therapy clinical trials using gene-modified HSCs (32–35). More 
recently, clinical trials of HSCT with HSCs genetically modified with self-inactivating (SIN) 
lentiviral vectors have proven the safety of this approach, showing high polyclonality and no 
expansion of clones with integrations near cancer-related genes previously associated with 
insertional mutagenesis (36–40). In the current clinical trial, we plan to use a SIN-lentiviral 
vector with an MSCV promoter derived from the MPSV murine gamma-retrovirus (41) to drive 
the expression of the transgenes. There is no prior clinical experience with this lentiviral vector. 
However, clinical trials using SIN-lentiviral vectors with the closely related MND promoter 
derived from the MPSV murine gamma-retrovirus (42) to drive the expression of the ABCD1 
gene have shown safety and lack of clonal expansion of the modified cells (43,44). Interestingly, 
Biffi et al. compared the integration profile of different lentiviruses in human HSCs engrafted in 
immunodeficient mice and showed that integration clustered in megabase-wide chromosomal 
regions of high lentiviral vector integration density demonstrating the bias toward specific 
genomic regions rather than by oncogenic selection (37). In line with these data, we 
demonstrated that the transduction of murine Lin- cells with our vector does not lead to 
transformation in vitro in contrast with the gamma-retroviral vector used as a positive control. 
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T cells are a self-renewing population, but we and others have previously shown that the their 
persistence is limited and associated to increased antitumor responses (4,5,8). HSC gene 
therapy holds great promise for immunotherapy due to the long-term persistence of the modified 
cells. Similar to the clinical trial proposed in this manuscript, the use of TCR genetically 
engineered HSCs has been proposed for HIV-1 therapy (45,46) in which feasibility has been 
shown in preclinical models. In line with this, cancer therapy and HIV-1 therapy approaches 
using chimeric antigen receptors (CARs) (47–49) and iNKT cell receptors (50) have been 
proposed in preclinical studies. These studies demonstrate the ability of HSCs to differentiate 
into functional T cells or invariant natural killer T (iNKT) cells expressing the selected antigen-
specific receptor and show antitumor activity or functional antiviral response to limit HIV-1 
replication. The co-administration of T cells together with HSCs is key to allow the HSCs to 
engraft and generate new functional T cells and at the same time provide a therapeutic effect, 
especially in patients with advanced disease.  
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Figure Legends 
 
Figure 1. Lentiviral and retroviral vector characterization. A. LV-NY-ESO-1 TCR/sr39TK 
(RRL-MSCV-optNYESO- optsr39TK-WPRE) self-inactivating third-generation lentiviral vector 
scheme. B. NY-ESO-1 TCR expression in human PBMCs three days after transduction. 
Percentage of NY-ESO-1 TCR and CD3 expression were measured by flow cytometry with 
NYESO-1(157-162) dextramer and anti-CD3 antibody in mock-transduced (top panel) and 
transduced (bottom panel) PBMCs. C. In vitro sr39TK functionality in hCD34+. Mock-transduced 
or LV-NY-ESO-1 TCR/sr39TK-transduced human CD34+ cells were treated with 0, 0.02, 0.2, 2, 
20 or 200µM ganciclovir (GCV) for 48 days. Left, TCR expression (measured by Vβ13 staining) 
in cells not treated with GCV. Percentage of Vβ13+ (center) and Vβ13- cells (right) in the 
transduced CD34+ cells after GCV treatment at the indicated concentrations. Vβ13 expression 
was measure by flow cytometry D. RV-NY-ESO-1 TCR (MSGV1-A2aB-1G4A-LY3H10) gamma-
retroviral vector scheme. E. NY-ESO-1 TCR expression in murine T cells from HLA-A2/Kb mice 
two days after transduction. Surface (top panels) and total (surface + intracellular, bottom 
panels) TCR expression was measured by Vβ13 TCR beta chain and surface CD3 staining 
detected by flow cytometry. Abbreviations: Ψ, packaging signal; cPPT, central polypurine tract; 
LTR, long terminal repeat; MSCV, murine stem cell virus promoter; RRE, Rev response 
element; SA, splicing acceptor; SD, splicing donor; WPRE, woodchuck hepatitis virus 
posttranslational response element. 
 
Figure 2. Co-administration of Lin- cells and T cells expressing NY-ESO-1 TCR does not 
have a negative impact on survival, body and organ weights, blood cell reconstitution 
and serum chemistry parameters three months after BMT. TCR engineered Lin- cells and T 
cells were co-administered to myelodepleted 8- to 12-week-old HLA-A2/Kb mice by intravenous 
injection. Mice from each cohort were euthanized at day 5 (n=6) or 3 months (n=12-15) after 
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BMT. A. Kaplan-Meier survival curve (Log-rank test p = 0.48). Numbers in the graph indicate 
survivor count at each time point. B. Total body weight. * p<0.05 vs untreated controls (cohort 
A), pair-wise comparisons of least-squares means in a linear model framework with Tukey-
Kramer adjustment within each time point; considered significant only if 5 or more consecutive 
measurements were significantly different. C. Organ weights at 3 months after BMT. D. 
Hematology at day 5 and 3 months after BMT. WBC, White Blood Cells; RBC, Red Blood Cells; 
HGB, Hemoglobin. E. White Blood Cell differential count at day 5 (left) and 3 months (right) after 
BMT. Neut, neutrophils; Lymphs, lymphocytes; Mono, monocytes; Eos, eosinophils; Baso, 
basophils; Bands, Band cells; Unclass, Unclassified cells. F. Serum chemistry at 3 months after 
BMT. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline 
phosphatase, serum; CK, creatine kinase; ALB, Albumin. Mean ±SEM is plotted. * p<0.05 vs 
cohort A, # p<0.05 compared to cohort E (receiving transduced Lin- and transduced T cells), 
pair-wise comparisons of least-squares means in a linear model framework with Tukey-Kramer 
adjustment within each time point.   
 
Figure 3. Co-administration of Lin- cells and T cells expressing an NY-ESO-1 TCR does 
not have a negative impact on stem cell and T cell engraftment and progeny persistence. 
Retrovirus vector copy number (VCN) in the blood, spleen and bone marrow at 5 days (n=6) (A) 
and 3 months (n=12-15) (B) after BMT. Lentivirus VCN in the blood, spleen and bone marrow at 
5 days (n=6) (C) and 3 months (n=12-15) (D) after BMT. Individual values and mean ±SEM are 
plotted. * p<0.05 vs cohorts A, B and C; # p<0.05 vs Cohorts A, B and D; & p<0.05 vs Cohorts 
D; pair-wise comparisons of least-squares means in a linear model framework with Tukey-
Kramer adjustment. 
 
Figure 4. The expression of NY-ESO-1 TCR in Lin- cells and their co-administration with T 
cells expressing an NY-ESO-1 TCR does not have a negative impact on hematopoietic 
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lineage differentiation. Bone marrow cells and splenocyte phenotype characterization 3 
months after BMT. TCR and cell surface markers were assessed by flow cytometry. A. 
Percentage of Lin- (left panel), LSK (Lin- ScaI+ cKit+, middle panel) and HSC (LSK CD150+ 
CD48-, right panel) cells in bone marrow. B. Percentage of NY-ESO-1 TCR-expressing cells in 
the bone marrow, detected by intracellular Vβ13 staining. C. Comparison of the frequency of Lin- 
(right), LSK (middle) and HSC (left) cells in the total bone marrow population (open circles) and 
the Vβ13+ population (closed circles). D. Percentages of NKT cells, CD4+ T cells, CD8+ T cells 
(left panel), B cells, granulocytes, macrophages and neutrophils (right panel) in the total 
splenocyte population, E. Percentage of NY-ESO-1 TCR-expressing cells in the splenocytes, 
detected by intracellular Vβ13 staining. F. Comparison of the frequency of NKT cells, CD4+T 
cells, CD8+ T cells (left panel), B cells, granulocytes, macrophages and neutrophils (right panel) 
in the total splenocyte population (open circles) and the Vβ13+ population (closed circles). 
Individual values and mean ±SEM are plotted (n=12-15).  * p<0.05 vs cohort A; # p<0.05 vs 
Cohort A, B and D; & p<0.05 vs Cohort A and B; + p<0.05; pair-wise comparisons of least-
squares means in a linear model framework with Tukey-Kramer adjustment. 
 
Figure 5. Lack of immunogenicity and genotoxicity of the LV-NY-ESO-1 TCR/sr39TK 
vector. Lin- cells transduced with either a LV-NY-ESO-1 TCR/sr39TK, LV-NY-ESO-1 TCR or 
LV-empty vector were transplanted into myelodepleted HLA-A2/Kb mice. Mice were euthanized 
at three months after BMT. A. Hematology at 3 months after BMT (n=5-9). WBC, White Blood 
Cells; RBC, Red Blood Cells; HGB, Hemoglobin. * p<0.05 vs untreated and # p<0.05 vs Mock-
transduced. Pair-wise Comparison with Tukey-Kramer. B. Lentivirus VCN in the bone marrow, 
spleen and blood at three months after BMT. The VCN is normalized with the VCN value of the 
transplanted cells. Mean ±SEM are plotted (n=6-9).  *p<0.05 vs untreated and # p<0.05 vs 
Mock-transduced. Pair-wise multiple comparison analysis using the Dwass, Steel, Critchlow-
Fligner method. C. In vitro immortalization assay. Replating frequency/VCN ratio for mock 
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transduced Lin- cells (n=3), Lin- cells transduced with SF91-eGFP-RRE (n=20) and Lin- cells 
transduced with the LV-NY-ESO-1 TCR/sr39TK (n=17). Fisher’s exact test (two-sided), p-value 
= 0.004, and Wilcoxon rank-sum test (two sided), p-value = 0.004, between the SF91-eGFP-
RRE transduced group and the LV-NYESO-1 TCR/sr39TK group. 
 
Figure 6. PBSC product stability. An aliquot of cryopreserved PBSC product was recovered at 
different time points post-cryopreservation: Thawed Cell Product (TCP Day 1, n=2), 30 days 
(TCP Day 30, n=5), 90 days (TCP Day 90, n=3) and 180 days (TCP Day 180, n=2) after 
cryopreservation (panels A and B). The stability parameters of the recovered PBSC product 
stored at RT or 4-8°C were analyzed after 3, 6, 24 and 48h post-thaw and compared to those at 
0h, (n=9), (Panels C – F). A. Total nucleated cells (TNC) viability (by trypan blue exclusion), 
CD34 recovery (by ISCHAGE method) and the percentage of TNCs that grew into 
hematopoietic colonies when cultured in MethoCult complete medium for 14 days (CFU 
potential) was assessed at different time points after the cryopreservation. There was no 
significant difference between the examined time points and fresh cell product (FCP) (p=0.17, 
p=0.31 and p=0.45 for TNC viability, CD34 recovery and CFU potential, respectively). Data are 
presented as mean±SD. B. The percentages of CFU-G/M/GM (colony-forming unit-
granulocyte/-macrophage/-granulocyte and macrophage), CFU-e/BFU-e (colony-forming unit-
erythroid/Burst-forming unit erythroid) and CFU-GEMM (colony-forming unit granulocyte, 
erythrocyte, monocyte, megakaryocyte) colonies after 14 days culture in MethoCult complete 
medium. Colonies were scored with the aid of a Zeiss Vert.A1 inverted microscope. Results are 
expressed as the percentage of CFU subtype per total cells plated. There were no statistically 
significant differences in the percentage of CFU-G/M/GM (p=0.24), CFU-e/BFU-e (p=0.68) and 
CFU-GEMM (p=0.52) between different time points and fresh CP. C. Percentage of viable TNC 
in the PBSC product at 0, 3, 6, 24 and 48h post thaw established by trypan blue exclusion 
essay. D. Percentage of viable CD34+ at 0, 3, 6, 24 and 48h post-thaw assessed by flow 
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cytometry (ISCHAGE method). E. Percentage of CD34 recovery at the different time points post 
thawing calculated by dividing “the number of CD34+ cells/ml at 0h” by the “number of CD34+ 
cells/ml at 3, 6, 24 and 48h time points” and multiplying by 100%. F. Clonogenic potential of the 
PBSC product 0, 3, 6, 24 and 48h post thaw measured by the percentage of TNCs that grew 
into hematopoietic colonies. The horizontal bars show averaged values (*p<0.05, **p<0.01 and 
***p<0.001 when compared to the 0h time point, by Tukey-Kramer test). 
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
Figure 1 
D A 
C 
Mock RV-NY-ESO-1 TCR 
E 
V
b
1
3
 
CD3 
B 
N
Y-
ES
O
-1
 D
ex
 
CD3 
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
0
5 0 0
1 0 0 0
1 5 0 0
P
la
te
le
ts
 (
x
1
0
³ 
/u
L
)
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
0
5
1 0
1 5
2 0
H
G
B
 (
g
 /
 d
L
)
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
0
5
1 0
1 5
R
B
C
 (
X
1
0
6
/u
L
)
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
D
a
y
 5
3
 m
o
n
th
0
2
4
6
8
W
B
C
 (
x
1
0
³ 
/u
L
)
Figure 2 
A 
D 
* 
* 
* * 
* 
* * * 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
B 
0 2 0 4 0 6 0 8 0
2 0
2 5
3 0
3 5
4 0
4 5
D a y  a fte r B M T
B
o
d
y
 w
e
ig
h
t 
(g
)
C 
* 
* 
* 
* 
* 
* 
* 
* 
* 
S
p
le
e
n
H
e
a
r t
L
iv
e
r  
K
id
n
e
y
s
U
r i
n
a
ry
 b
la
d
d
e
r
O
v
a
ry
U
te
ru
s
T
e
s
te
s
 
B
ra
in
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
W
e
ig
h
t 
(g
)
E 
ALT
0
200
400
600
800
1000
A
L
T
 (
U
/L
)
ALT
Untreated
Mock Lin- + Mock Tc
TCR/TK Lin- + Mock Tc
Mock Lin- + TCR Tc
TCR/TK Lin- + TCR Mock
F 
AST
0
500
1000
1500
A
S
T
 (
U
/L
)
AST
Untreated
Mock Lin- + Mock Tc
TCR/TK Lin- + Mock Tc
Mock Lin- + TCR Tc
TCR/TK Lin- + TCR Mock
* 
ALP
0
50
100
150
200
A
L
P
 (
U
/L
)
ALP
Untreated
Mock Lin- + Mock Tc
TCR/TK Lin- + Mock Tc
Mock Lin- + TCR Tc
TCR/TK Lin- + TCR Mock
* 
CK
0
2000
4000
6000
8000
10000
C
K
 (
U
/L
)
CK
Untreated
Mock Lin- + Mock Tc
TCR/TK Lin- + Mock Tc
Mock Lin- + TCR Tc
TCR/TK Lin- + TCR Mock
* 
# 
# 
# 
ALB
2.0
2.5
3.0
3.5
4.0
A
L
B
 (
g
/d
L
)
ALB
Untreated
Mock Lin- + Mock Tc
TCR/TK Lin- + Mock Tc
Mock Lin- + TCR Tc
TCR/TK Lin- + TCR Mock
* 
# 
N E U T L Y M P H S M O N O E O S B A S O B A N D S U n c la s s
0
2
4
6
8
T
o
ta
l 
c
o
u
n
ts
 (
x
1
0
³ 
/
u
L
)
N E U T L Y M P H S M O N O E O S B A S O B A N D S U n c la s s
0
2
4
6
8
T
o
ta
l 
c
o
u
n
ts
 (
x
1
0
³ 
/
u
L
)
* * * * 
* * * * * * * * * * * * 
0 2 0 4 0 6 0 8 0
0
5 0
1 0 0
T im e  (D a y s )
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
   16     1 6    16  1 6 15
   16      1 6    15  15 15
   16      1 5    15  14  12
   16      1 5    14  14 14
   16      1 5    15  15 15
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
0 .00
0 .05
0 .10
0 .15
R
e
tr
o
v
ir
u
s
 V
C
N
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
0 .00
0 .02
0 .04
0 .06
0 .08
0 .10
R
e
tr
o
v
ir
u
s
 V
C
N
A B 
* * 
* 
* * 
* 
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
L
e
n
ti
v
ir
u
s
 V
C
N
C 
# 
# 
# 
# 
# 
# 
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
B
lo
o
d
S
p
le
e
n
B
o
n
e
 M
a
rr
o
w
-1
0
1
2
3
L
e
n
ti
v
ir
u
s
 V
C
N
D 
# # # 
# 
# 
# 
* 
* 
* 
* 
* 
* 
& 
Figure 3 
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
Figure 5 
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
P
la
te
le
ts
 (
x
1
0
³ 
/u
L
)
A 
B 
* 
# 
B
M
S
p
le
e
n
B
lo
o
d
-2
0
2
4
6
V
C
N
 (
n
o
r
m
a
li
z
e
d
)
U n tre a ted L V  e m p ty L V  N Y E S O  T C R -s r3 9 T KL V  N Y E S O  T C RM o c k
B
M
S
p
le
e
n
B
lo
o
d
0
1
2
3
4
5
V
C
N
 (
n
o
r
m
a
li
z
e
d
)
0
2
4
6
8
1 0
W
B
C
 (
x
1
0
³ 
/u
L
)
0
5
1 0
1 5
R
B
C
 (
X
1
0
6
/u
L
)
0
5
1 0
1 5
2 0
H
G
B
 (
g
 /
 d
L
)
C 
* * 
* 
* * 
* 
# 
# 
# 
# # 
# # 
# 
# 
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
Figure 6 
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
 Published OnlineFirst November 8, 2018.Clin Cancer Res 
  
Cristina Puig-Saus, Giulia Parisi, Angel Garcia-Diaz, et al. 
  
persistent cancer-targeted immune system
IND-enabling studies for a clinical trial to genetically program a
  
Updated version
  
 10.1158/1078-0432.CCR-18-0963doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2018/11/08/1078-0432.CCR-18-0963.DC1
Access the most recent supplemental material at:
  
Manuscript
Author
edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2018/11/08/1078-0432.CCR-18-0963
To request permission to re-use all or part of this article, use this link
Research. 
on November 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 8, 2018; DOI: 10.1158/1078-0432.CCR-18-0963 
